Evidence map›Paper›PMID 39384609›Full record

Trial reportBlood cancer journal2024

Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma.

Surbhi Sidana, Andriyana K Bankova, Hitomi Hosoya, Shaji K Kumar, Tyson H Holmes, John Tamaresis, Anne Le, Lori S Muffly, Sofia Maysel-Auslender, Laura Johnston and 11 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04552743 (Phase II Study of MGTA-145 in Combination With Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Patients With Multiple Myeloma), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04552743 phase2completednot on this map

Phase II Study of MGTA-145 in Combination With Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Patients With Multiple Myeloma

TypeinterventionalSponsorSurbhi Sidana, MDRan2020 to 2022Enrolled25ConditionsMultiple MyelomaArmsMGTA-145, Plerixafor
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Surbhi SidanaDivision of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA. Surbhi.sidana@stanford.edu.ORCID 0000-0003-3288-7614
Andriyana K BankovaDivision of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA.
Hitomi HosoyaDivision of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA.
Shaji K KumarDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-5392-9284
Tyson H HolmesInstitute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, USA.
John TamaresisDepartment of Biostatistics, Stanford University School of Medicine, Stanford, USA.ORCID 0000-0002-9868-2366
Anne LeDivision of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA.
Lori S MufflyDivision of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA.ORCID 0000-0002-9887-6136
Sofia Maysel-AuslenderInstitute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, USA.
Laura JohnstonDivision of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA.
Sally AraiDivision of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA.
Robert LowskyDivision of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA.
Everett MeyerDivision of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA.
Andrew RezvaniDivision of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA.
Wen-Kai WengDivision of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA.
Matthew J FrankDivision of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA.
Parveen ShirazDivision of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA.
Holden T MaeckerInstitute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, USA.
Ying LuDepartment of Biostatistics, Stanford University School of Medicine, Stanford, USA.ORCID 0000-0002-7698-8962
David B MiklosDivision of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA.ORCID 0000-0003-0717-4305
Judith A ShizuruDivision of BMT and Cell Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, USA.ORCID 0000-0003-3246-4726

Funding

Institutional Career Development Core (KL2)KL2TR003143 · NCATS · STANFORD UNIVERSITY · PI ASCH, STEVEN M. · 2019 to 2023
$8.7M
CyTOF Mass CytometerS10RR027582 · NCRR · STANFORD UNIVERSITY · PI NOLAN, GARRY P · 2010 to 2010
$500k
NCATS NIH HHS KL2 TR003143NCRR NIH HHS S10 RR027582
6 · The paper itself

Abstract

MGTA-145 or GROβT, a CXCR2 agonist, has shown promising activity for hematopoietic stem cell (HSC) mobilization with plerixafor in pre-clinical studies and healthy volunteers. Twenty-five patients with multiple myeloma enrolled in a phase 2 trial evaluating MGTA-145 and plerixafor for HSC mobilization (NCT04552743). Plerixafor was given subcutaneously followed 2 h later by MGTA-145 (0.03 mg/kg) intravenously with same day apheresis. Mobilization/apheresis could be repeated for a second day in patients who collected <6 ×10

Indexed as

BenzylaminesCyclamsHematopoietic Stem Cell MobilizationHeterocyclic CompoundsMultiple MyelomaReceptors, Interleukin-8BAdultAgedFemaleHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedBenzylaminesCXCR2 protein, humanCyclamsHeterocyclic CompoundsplerixaforReceptors, Interleukin-8B

Identifiers

PMID39384609
PMCPMC11464886

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.